Smoldering Type Adult T-cell Leukemia/lymphoma Effectively Treated with Mogamulizumab (anti-CC Chemokine Receptor 4 Monoclonal Antibody)-A Case Report

Overview

Journal Clin Case Rep

Date 2019 May 22

PMID 31110745

Citations 1

Authors

Yotaro Nishikawa

Kosuke Mochida

Tamaki Kubo

Nagako Horikawa

Rieko Nemoto

Masahiro Amano

Affiliations

Soon will be listed here.

Abstract

The use of mogamulizumab needs careful consideration because of severe adverse reactions such as graft-vs-host disease. However, refractory specific skin lesions of smoldering type adult T-cell leukemia/lymphoma can be effectively treated with mogamulizumab when patients have no opportunity to receive hematopoietic stem cell transplantation like our case.

Citing Articles

Smoldering type adult T-cell leukemia/lymphoma effectively treated with mogamulizumab (anti-CC chemokine receptor 4 monoclonal antibody)-A case report.

Nishikawa Y, Mochida K, Kubo T, Horikawa N, Nemoto R, Amano M Clin Case Rep. 2019; 7(5):1057-1061.

PMID: 31110745 PMC: 6509667. DOI: 10.1002/ccr3.2155.

References

Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H . Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010; 16(5):1520-31. DOI: 10.1158/1078-0432.CCR-09-2697. View

Amano M, Setoyama M, Grant A, Kerdel F . Human T-lymphotropic virus 1 (HTLV-1) infection--dermatological implications. Int J Dermatol. 2011; 50(8):915-20. DOI: 10.1111/j.1365-4632.2011.04882.x. View

Sawada Y, Shimauchi T, Yamaguchi T, Okura R, Hama-Yamamoto K, Fueki-Yoshioka H . Combination of skin-directed therapy and oral etoposide for smoldering adult T-cell leukemia/lymphoma with skin involvement. Leuk Lymphoma. 2012; 54(3):520-7. DOI: 10.3109/10428194.2012.715351. View

Fuji S, Shindo T . Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. Stem Cell Investig. 2016; 3:70. PMC: 5104570. DOI: 10.21037/sci.2016.09.13. View

Yonekura K, Tokunaga M, Kawakami N, Takeda K, Kanzaki T, Nakano N . Cutaneous Adverse Reaction to Mogamulizumab May Indicate Favourable Prognosis in Adult T-cell Leukaemia-lymphoma. Acta Derm Venereol. 2016; 96(7):1000-1002. DOI: 10.2340/00015555-2421. View

Tokunaga M, Yonekura K, Nakamura D, Haraguchi K, Tabuchi T, Fujino S . Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma. Br J Haematol. 2017; 181(4):539-542. DOI: 10.1111/bjh.14634. View

Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S . Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012; 30(8):837-42. DOI: 10.1200/JCO.2011.37.3472. View

Utsunomiya A, Choi I, Chihara D, Seto M . Recent advances in the treatment of adult T-cell leukemia-lymphomas. Cancer Sci. 2015; 106(4):344-51. PMC: 4409876. DOI: 10.1111/cas.12617. View

Sugio T, Kato K, Aoki T, Ohta T, Saito N, Yoshida S . Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016; 22(9):1608-1614. DOI: 10.1016/j.bbmt.2016.05.017. View

10.

Nishikawa Y, Mochida K, Kubo T, Horikawa N, Nemoto R, Amano M . Smoldering type adult T-cell leukemia/lymphoma effectively treated with mogamulizumab (anti-CC chemokine receptor 4 monoclonal antibody)-A case report. Clin Case Rep. 2019; 7(5):1057-1061. PMC: 6509667. DOI: 10.1002/ccr3.2155. View

11.

Ishitsuka K, Yurimoto S, Kawamura K, Tsuji Y, Iwabuchi M, Takahashi T . Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance. Int J Hematol. 2017; 106(4):522-532. DOI: 10.1007/s12185-017-2270-9. View

12.

Inozume T, Matsue H, Furuhashi M, Nakamura Y, Mitsui H, Ando N . Successful use of etretinate for long-term management of a patient with cutaneous-type adult T-cell leukaemia/lymphoma. Br J Dermatol. 2005; 153(6):1239-41. DOI: 10.1111/j.1365-2133.2005.06974.x. View